IDEXX Labs (IDXX) Tops Q3 EPS by 2c; Updates FY16 Outlook; Guides FY17 EPS Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
IDEXX Laboratories Announces Third Quarter Results
November 1, 2016 7:00 AM EDTWESTBROOK, Maine, Nov. 1, 2016 /PRNewswire/ --
Reports revenue growth of 10% on both a reported and organic basis, reflecting CAG Diagnostics recurring revenue growth of 12% and strong premium instrument placements Delivers EPS of $0.62, a 29% increase year over year as reported, or 22% on an Adjusted constant currency basis Achieves 18% growth in premium instrument placements, including 562 IDEXX SediVue Dx placements Adjusts 2016 revenue growth and EPS outlook toward the high end of previous guidance range, and provides preliminary 2017 financial guidance for organic revenue growth of 9% - 10.5% and earnings per share... More